Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.50 |
| ▸ | F2R | P25116 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901310 | 0.98 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL3199790 | 0.98 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL19359643 | 0.98 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL9951287 | 0.98 | NAAA (0.56) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL22139787 | 0.89 | NAAA (0.44) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL5902012 | 0.88 | NAAA (0.59) | NAAAEPHX1ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL9831292 | 0.86 | NAAA (0.62) | NAAAEPHX1ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL6502279 | 0.86 | NAAA (0.62) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL2678008 | 0.86 | NAAA (0.62) | NAAAEPHX1ITGB3ITGA2BF2R | |
| SCHEMBL12999518 | 0.86 | ITGB3 (0.43) | NAAAITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102319184-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| CN-102319184-A | Parakeratosis inhibitor, pore contracting agent and composition for external application | SHISEIDO CO LTD | 2012-01-18 | — | — | CN | disclosed |
| CN-101175470-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2011-09-14 | — | — | CN | disclosed |
| CN-101267803-B | Wrinkle-improving agent | SHISEIDO CO LTD | 2011-06-08 | — | — | CN | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| CN-101267803-A | Wrinkle-improving agent | SHISEIDO CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-6878708-B2 | Imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20050049250-A1 | 7-Aikyl and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1280805-B1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-6838459-B1 | 7-alkyl-and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-01-04 | — | — | US | disclosed |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| EP-1280805-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-6476029-B1 | 7-alkyl- and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| WO-2001064677-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
| EP-1090003-A1 | 7-ALKYL- AND CYCLOALKYL-SUBSTITUTED IMIDAZOTRIAZINONES | Bayer Aktiengesellschaft (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067244-A1 | 7-ALKYL- AND CYCLOALKYL-SUBSTITUTED IMIDAZOTRIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | NAAA 67/4885EPHX1 3679/4885ITGB3 3711/4885 |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | CYP4F3, CYP4F2, CYP3A7 | NAAA 3998/4885EPHX1 2316/4885ITGB3 4221/4885 |
| US-20050049250-A1 | 7-Aikyl and cycloalkyl-substituted imidazotriazinones | PDE3A, PDE2A, PDE3B | NAAA 723/4885EPHX1 1979/4885ITGB3 3898/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | NAAA 177/4885EPHX1 3301/4885ITGB3 4773/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | NAAA 76/4885EPHX1 3879/4885ITGB3 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.